AMENDMENT NO. 2 TO COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • November 14th, 2005 • Xenogen Corp • Measuring & controlling devices, nec
THIS AMENDMENT NO. 2 (“Amendment No. 2”), effective as of October 4, 2005 (the “Amendment Effective Date”), is made by and between Xenogen Corporation, having its principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and Novartis Institutes for BioMedical Research, Inc., having its principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“NIBRI”).
